Incyte (INCY) and Mirati Therapeutics (MRTX) announced a clinical trial collaboration and supply agreement to investigate the combination of INCB99280, Incyte’s small molecule PD-L1 inhibitor, and adagrasib, a KRASG12C selective inhibitor. Under the terms of the agreement, Incyte will initiate and sponsor the Phase 1/1b study of INCB99280 and adagrasib in patients with KRASG12C-mutated solid tumors. Mirati will supply Incyte with adagrasib for the study.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on INCY:
- Early notable gainers among liquid option names on November 1st
- Incyte reports Q3 EPS 60c, consensus 72c
- Incyte price target lowered to $80 from $86 at JPMorgan
- Incyte’s ruxolitinib cream shows repigmentation efficacy in Phase 3 trial
- BriaCell adds new site to Phase 1/2 trial of advanced breast cancer candidate